Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Dorzolamide hydrochloride [USAN:USP]
RN: 130693-82-2
UNII: QZO5366EW7
InChIKey: OSRUSFPMRGDLAG-QMGYSKNISA-N

Note

  • Topically effective ocular hypotensive carbonic anhydrase inhibitor.

Molecular Formula

  • C10-H16-N2-O4-S3.Cl-H

Molecular Weight

  • 360.9053
 

Classification Codes

  • Antihypertensive Agents
  • Carbonic Anhydrase Inhibitor
  • Carbonic Anhydrase Inhibitors
  • Cardiovascular Agents
  • Drug / Therapeutic Agent
  • Enzyme Inhibitors
  • Reproductive Effect

Names and Synonyms

Name of Substance

  • Dorzolamide
  • Dorzolamide hydrochloride [USAN:USP]

Synonyms

  • (4S,6S)-4-(Ethylamino)-5,6-dihydro-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide 7,7-dioxide, monohydrochloride
  • 4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide, monohydrochloride, (4S-trans)-
  • Dorzolamide HCl
  • Dorzolamide hydrochloride
  • L 671152
  • L-671,152
  • MK 0507
  • MK-0507
  • MK-507
  • Trusopt
  • UNII-QZO5366EW7

Systematic Names

  • 4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide, monohydrochloride, (4S-trans)-
  • 4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 5,6-dihydro-4-(ethylamino)-6-methyl-, 7,7-dioxide, monohydrochloride, (4S,6S)-

Mixture Name

  • Cosopt

Registry Numbers

CAS Registry Number

  • 130693-82-2

FDA UNII

  • QZO5366EW7

System Generated Number

  • 0130693822

Molecular Formulas

Molecular Formula

  • C10-H16-N2-O4-S3.Cl-H

Molecular Formula Fragments

  • C10-H16-N2-O4-S3
  • Cl-H
  • COMPONENT

Structure Descriptors

InChI

1S/C10H16N2O4S3.ClH/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16;/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16);1H/t6-,8-;/m0./s1

InChIKey

OSRUSFPMRGDLAG-QMGYSKNISA-N

Smiles

Cl.CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(=O)(=O)N

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LD50 oral > 250mg/kg (250mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 1241, 1994.
mouse LD50 intravenous 469mg/kg (469mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 1241, 1994.
mouse LD50 oral 1320mg/kg (1320mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE

BEHAVIORAL: ATAXIA
Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 1241, 1994.
mouse LD50 subcutaneous > 2gm/kg (2000mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: ATAXIA

SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE
Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 1241, 1994.
rat LD50 intravenous 726mg/kg (726mg/kg) BEHAVIORAL: TREMOR

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 1241, 1994.
rat LD50 oral 1927mg/kg (1927mg/kg) BEHAVIORAL: ATAXIA

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE
Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 1241, 1994.
rat LD50 subcutaneous > 2gm/kg (2000mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE

SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"
Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 1241, 1994.